Supplemental Material for "Increased risk of COVID-19-related hospitalization in patients with hidradenitis suppurativa compared with controls"

Table S1. Patient eligibility flowchart – Page 2 Table S2. Definitions for exposures, outcomes, and covariates – Pages 3-7 Table S3. Risk of hospitalization for COVID-19 in HS patients and control patients – Page 8 Table S4. Demographic and clinical characteristics according to treatment group – Pages 9-10 Table S5. Incidence of COVID-19 hospitalization among hidradenitis suppurativa patients according to use of biologics and traditional immunosuppressives – Page 11 Table S6. Complete demographic and clinical characteristics of patients with HS and controls – Pages 12- 13附表S1 患者入组流程图——第2页 附表S2 暴露因素、结局与协变量的定义——第3至7页 附表S3 化脓性汗腺炎（hidradenitis suppurativa, HS）患者与对照患者的COVID-19住院风险——第8页 附表S4 按治疗分组划分的人口学与临床特征——第9至10页 附表S5 按生物制剂与传统免疫抑制剂使用情况划分的化脓性汗腺炎患者COVID-19住院发生率——第11页 附表S6 化脓性汗腺炎患者与对照患者的完整人口学与临床特征——第12至13页